Aldesleukin by Iovance Biotherapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval

Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).

Kessler Foundation researchers receive $1.7 million in grants to improve lives of TBI patients

Kessler Foundation scientists received four grants from the New Jersey Commission on Brain Injury Research, totaling nearly $1.7 million for studies based on a variety

August 16, 2023

KFF Health News’ ‘What the Health?’: Health funding in question in a speaker-less Congress

As House Republicans struggle — again — to decide who will lead them, the clock is ticking on a short-term spending bill that keeps the

October 12, 2023

Associations between ultra-processed food consumption and phthalate exposures in pregnant women

Researchers explored the relationship between consuming ultra-processed foods and urinary phthalate concentrations during pregnancy.

February 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.